Search

Your search keyword '"Brescia Morra"' showing total 1,596 results
Start Over Author "Brescia Morra"
1,596 results on '"Brescia Morra"'

1. Disability trajectories by progression independent of relapse activity status differ in pediatric, adult and late-onset multiple sclerosis

Author

Simone, Marta, Lucisano, Giuseppe, Guerra, Tommaso, Paolicelli, Damiano, Rocca, Maria A., Brescia Morra, Vincenzo, Patti, Francesco, Annovazzi, Pietro, Gasperini, Claudio, De Luca, Giovanna, Ferraro, Diana, Margari, Lucia, Granella, Franco, Pozzilli, Carlo, Romano, Silvia, Perini, Paola, Bergamaschi, Roberto, Coniglio, Maria Gabriella, Lus, Giacomo, Vianello, Marika, Lugaresi, Alessandra, Portaccio, Emilio, Filippi, Massimo, Amato, Maria Pia, and Iaffaldano, Pietro

Published
2024
Full Text
View/download PDF

2. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod

Author

Carotenuto, Antonio, Di Monaco, Cristina, Papetti, Laura, Borriello, Giovanna, Signoriello, Elisabetta, Masciulli, Camilla, Tomassini, Valentina, De Luca, Giovanna, Ianniello, Antonio, Lus, Giacomo, Novarella, Federica, Spiezia, Antonio Luca, Di Somma, Dario, Moccia, Marcello, Petracca, Maria, Iacovazzo, Carmine, Servillo, Giuseppe, Portaccio, Emilio, Triassi, Maria, Amato, Maria Pia, Pozzilli, Carlo, Valeriani, Massimiliano, Brescia Morra, Vincenzo, and Lanzillo, Roberta

Published
2024
Full Text
View/download PDF

4. Progression independent of relapse activity in relapsing multiple sclerosis: impact and relationship with secondary progression

Author

Portaccio, Emilio, Betti, Matteo, De Meo, Ermelinda, Addazio, Ilaria, Pastò, Luisa, Razzolini, Lorenzo, Totaro, Rocco, Spitaleri, Daniele, Lugaresi, Alessandra, Cocco, Eleonora, Onofrj, Marco, Di Palma, Franco, Patti, Francesco, Maimone, Davide, Valentino, Paola, Torri Clerici, Valentina, Protti, Alessandra, Ferraro, Diana, Lus, Giacomo, Maniscalco, Giorgia Teresa, Brescia Morra, Vincenzo, Salemi, Giuseppe, Granella, Franco, Pesci, Ilaria, Bergamaschi, Roberto, Aguglia, Umberto, Vianello, Marika, Simone, Marta, Lepore, Vito, Iaffaldano, Pietro, Comi, Giancarlo, Filippi, Massimo, Trojano, Maria, and Amato, Maria Pia

Published
2024
Full Text
View/download PDF

7. Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity

Author

Lepore, Maria Teresa, Bruzzaniti, Sara, La Rocca, Claudia, Fusco, Clorinda, Carbone, Fortunata, Mottola, Maria, Zuccarelli, Bruno, Lanzillo, Roberta, Brescia Morra, Vincenzo, Maniscalco, Giorgia Teresa, De Simone, Salvatore, Procaccini, Claudio, Porcellini, Antonio, De Rosa, Veronica, Galgani, Mario, Cassano, Silvana, and Matarese, Giuseppe

Published
2024
Full Text
View/download PDF

8. Dysphagia assessment in patients with multiple sclerosis – an additional piece to disability burden

Author

Davide Ranucci, Fabrizia Falco, Valerio Nicolella, Cristina Di Monaco, Laura Migliaccio, Federica Lamagna, Federica Caracciolo, Martina Eliano, Maria Petracca, Marcello Moccia, Vincenzo Brescia Morra, Antonio Carotenuto, and Roberta Lanzillo

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Objective People with multiple sclerosis (MS) might experience symptoms that are usually underestimated. Dysphagia should be evaluated within the Expanded Disability Status Scale (EDSS), but clinicians often do not assess it properly. The objectives of this study are as follows: To assess the prevalence of dysphagia in patients with MS utilizing the Swallowing Disturbance Questionnaire (SDQ); to examine the correlation with the EDSS; to investigate the relationship between dysphagia and clinico‐demographic characteristics of MS. Methods In total, 177 MS patients underwent evaluations with EDSS, SDQ, cognitive functions, anxiety, depression, fatigue, and sleep quality tests. We compared clinico‐demographic data of patients with and without dysphagia and native‐EDSS to SDQ‐EDSS. Results Out of the 177 MS patients, 56% of individuals were identified having dysphagia according to the SDQ with 41 patients exhibiting mild dysphagia, 31 showing moderate dysphagia and 27 patients having severe dysphagia. Only 6 patients had dysphagia recorded in the EDSS. SDQ‐EDSS scores were significantly higher than native scores. Dysphagia was associated with depressive symptoms and sleep quality. Interpretation Dysphagia affects up to 56% of MS patients. The SDQ questionnaire is useful for identifying dysphagia, which can help in capturing disease progression and preventing complications like aspiration pneumonia. The SDQ‐EDSS was higher than the native‐EDSS, reflecting the poor ability of the native‐EDSS to evaluate certain symptoms such as dysphagia. The SDQ correlated with depressive symptoms, which are associated with a greater perception of MS symptoms, and poor sleep quality, which could be associated with the triggering of pathogenic mechanisms responsible for disease progression.

Published
2024
Full Text
View/download PDF

10. JC virus antibody index in natalizumab-treated patients: correlations with John Cunningham virus DNA and C-reactive protein level

Author

Lanzillo R, Liuzzi R, Vallefuoco L, Moccia M, Amato L, Vacca G, Vacchiano V, Portella G, and Brescia Morra V

Subjects
Therapeutics. Pharmacology, RM1-950
Abstract

Roberta Lanzillo,1 Raffaele Liuzzi,2 Luca Vallefuoco,3 Marcello Moccia,1 Luca Amato,1 Giovanni Vacca,1 Veria Vacchiano,1 Giuseppe Portella,3 Vincenzo Brescia Morra1 1Neurological Sciences Department, Federico II University, 2Institute of Biostructure and Bioimaging, National Research Council, 3Clinical Pathology Department, Federico II University, Naples, ItalyAbstract: Natalizumab-treated patients have a higher risk of developing progressive multifocal leukoencephalopathy. Exposure to John Cunningham virus (JCV) is a prerequisite for PML (progressive multifocal leukoencephalopathy). To assess JCV exposure in multiple sclerosis patients, we performed a serological examination, obtained the antibody index, performed real-time polymerase chain reaction (PCR) to detect JCV DNA in plasma and urine, and investigated the role of ultrasensitive C-reactive protein (usCRP) as a possible biological marker of JCV reactivation. We retrospectively analyzed consecutive natalizumab-treated multiple sclerosis patients who underwent a JCV antibody test through a two-step enzyme-linked immunosorbent assay (STRATIFY test) to the measure of serum usCRP levels, and to perform blood and urine JCV PCR. The studied cohort included 97 relapsing–remitting patients (60 women). Fifty-two patients (53.6%) tested positive for anti-JCV antibodies. PCR showed JCV DNA in the urine of 30 out of 83 (36.1%) patients and 28 out of 44 seropositive patients (63.6%), with a 6.7% false-negative rate for the STRATIFY test. Normalized optical density values were higher in urinary JCV DNA-positive patients (P

Published
2014

11. A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis

Author

Pietro Iaffaldano, Giuseppe Lucisano, Tommaso Guerra, Damiano Paolicelli, Emilio Portaccio, Matilde Inglese, Matteo Foschi, Francesco Patti, Franco Granella, Silvia Romano, Paola Cavalla, Giovanna De Luca, Paolo Gallo, Paolo Bellantonio, Antonio Gallo, Sara Montepietra, Alessia Di Sapio, Marika Vianello, Rocco Quatrale, Daniele Spitaleri, Raffaella Clerici, Valentina Torri Clerici, Eleonora Cocco, Vincenzo Brescia Morra, Girolama Alessandra Marfia, Vincenzo Daniele Boccia, Massimo Filippi, Maria Pia Amato, Maria Trojano, and the Italian MS Register

Subjects
Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Objective No direct comparisons of the effect of natalizumab and ocrelizumab on progression independent of relapse activity (PIRA) and relapse‐associated worsening (RAW) events are currently available. We aimed to compare the risk of achieving first 6 months confirmed PIRA and RAW events and irreversible Expanded Disability Status Scale (EDSS) 4.0 and 6.0 in a cohort of naïve patients treated with natalizumab or ocrelizumab from the Italian Multiple Sclerosis Register. Methods Patients with a first visit within 1 year from onset, treated with natalizumab or ocrelizumab, and ≥3 visits were extracted. Pairwise propensity score‐matched analyses were performed. Risk of reaching the first PIRA, RAW, and EDSS 4.0 and 6.0 events were estimated using multivariable Cox proportional hazards models. Kaplan–Meier curves were used to show cumulative probabilities of reaching outcomes. Results In total, 770 subjects were included (natalizumab = 568; ocrelizumab = 212) and the propensity score‐matching retrieved 195 pairs. No RAW events were found in natalizumab group and only 1 was reported in ocrelizumab group. A first PIRA event was reached by 23 natalizumab and 25 ocrelizumab exposed patients; 7 natalizumab‐ and 10 ocrelizumab‐treated patients obtained an irreversible EDSS 4.0, while 13 natalizumab‐ and 15 ocrelizumab‐treated patients reached an irreversible EDSS 6.0. No differences between the two groups were found in the risk (HR, 95%CI) of reaching a first PIRA (1.04, 0.59–1.84; p = 0.88) event, an irreversible EDSS 4.0 (1.23, 0.57–2.66; p = 0.60) and 6.0 (0.93, 0.32–2.68; p = 0.89). Interpretation Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different.

Published
2024
Full Text
View/download PDF

12. Deciphering the role of protein kinase A in the control of FoxP3 expression in regulatory T cells in health and autoimmunity

Author

Maria Teresa Lepore, Sara Bruzzaniti, Claudia La Rocca, Clorinda Fusco, Fortunata Carbone, Maria Mottola, Bruno Zuccarelli, Roberta Lanzillo, Vincenzo Brescia Morra, Giorgia Teresa Maniscalco, Salvatore De Simone, Claudio Procaccini, Antonio Porcellini, Veronica De Rosa, Mario Galgani, Silvana Cassano, and Giuseppe Matarese

Subjects
Medicine, Science
Abstract

Abstract The molecular mechanisms that govern differential T cell development from CD4+CD25-conventional T (Tconv) into CD4+CD25+ forkhead-box-P3+ (FoxP3+) inducible regulatory T (iTreg) cells remain unclear. Herein, we investigated the relative contribution of protein kinase A (PKA) in this process. Mechanistically, we found that PKA controlled the efficiency of human iTreg cell generation through the expression of different FoxP3 splicing variants containing or not the exon 2. We found that transient PKA inhibition reduced the recruitment of cAMP-responsive element-binding protein (CREB) on regulatory regions of the FoxP3 gene, a condition that is associated with an impaired acquisition of their suppressive capacity in vitro. To corroborate our findings in a human model of autoimmunity, we measured CREB phosphorylation and FoxP3 levels in iTreg cells from treatment-naïve relapsing–remitting (RR)-multiple sclerosis (MS) subjects. Interestingly, both phospho-CREB and FoxP3 induction directly correlated and were significantly reduced in RR-MS patients, suggesting a previously unknown mechanism involved in the induction and function of human iTreg cells.

Published
2024
Full Text
View/download PDF

13. Evaluation of drivers of treatment switch in relapsing multiple sclerosis: a study from the Italian MS Registry

Author

Iaffaldano, Pietro, Lucisano, Giuseppe, Guerra, Tommaso, Patti, Francesco, Cocco, Eleonora, De Luca, Giovanna, Brescia Morra, Vincenzo, Pozzilli, Carlo, Zaffaroni, Mauro, Ferraro, Diana, Gasperini, Claudio, Salemi, Giuseppe, Bergamaschi, Roberto, Lus, Giacomo, Inglese, Matilde, Romano, Silvia, Bellantonio, Paolo, Di Monte, Elisabetta, Maniscalco, Giorgia Teresa, Conte, Antonella, Lugaresi, Alessandra, Vianello, Marika, Torri Clerici, Valentina Liliana Adriana, Di Sapio, Alessia, Pesci, Ilaria, Granella, Franco, Totaro, Rocco, Marfia, Girolama Alessandra, Danni, Maura Chiara, Cavalla, Paola, Valentino, Paola, Aguglia, Umberto, Montepietra, Sara, Ferraro, Elisabetta, Protti, Alessandra, Spitaleri, Daniele, Avolio, Carlo, De Riz, Milena, Maimone, Davide, Cavaletti, Guido, Gazzola, Paola, Tedeschi, Gioacchino, Sessa, Maria, Rovaris, Marco, Di Palma, Franco, Gatto, Maurizia, Cargnelutti, Daniela, De Robertis̄, Francesca, Logullo, Francesco Ottavio, Rini, Augusto, Meucci, Giuseppe, Ardito, Bonaventura, Banfi, Paola, Nasuelli, Davide, Paolicelli, Damiano, Rocca, Maria Assunta, Portaccio, Emilio, Chisari, Clara Grazia, Fenu, Giuseppe, Onofrj, Marco, Carotenuto, Antonio, Ruggieri, Serena, Tortorella, Carla, Ragonese, Paolo, Nica, Mihaela, Amato, Maria Pia, Filippi, Massimo, and Trojano, Maria

Published
2024
Full Text
View/download PDF

15. Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched study

Author

Clara G. Chisari, Umberto Aguglia, Maria Pia Amato, Roberto Bergamaschi, Antonio Bertolotto, Simona Bonavita, Vincenzo Brescia Morra, Paola Cavalla, Eleonora Cocco, Antonella Conte, Salvatore Cottone, Giovanna De Luca, Alessia Di Sapio, Massimo Filippi, Antonio Gallo, Claudio Gasperini, Franco Granella, Giacomo Lus, Davide Maimone, Giorgia Teresa Maniscalco, Girolama Marfia, Lucia Moiola, Damiano Paolicelli, Ilaria Pesci, Paolo Ragonese, Marco Rovaris, Giuseppe Salemi, Claudio Solaro, Rocco Totaro, Maria Trojano, Marika Vianello, Mauro Zaffaroni, Vito Lepore, Francesco Patti, Carlo Avolio, Roberto Balgera, Paola Banfi, Paolo Bellantonio, Placido Bramanti, Lorenzo Capone, Guido Cavalletti, Luca Chiveri, Raffaella Clerici, Marinella Clerico, Francesco Corea, Vincenzo Dattola, Francesca De Robertis, Giancarlo Di Battista, Simonetta Galgani, Maurizia Gatto, Maria Grazia Grasso, Matilde Inglese, Lorenzo Lo Russo, Francesco Ottavio Logullo, Renato Mantegazza, Alessandra Protti, Monica Rezzonico, Mariarosa Rottoli, Marco Salvetti, Elio Scarpini, Leonardo Sinisi, Maddalena Sparaco, Daniele Spitaleri, Tiziana Tassinari, Simone Tonietti, Paola Valentino, Franco Valzania, and Simonetta Venturi

Subjects
Natalizumab, Interferon beta 1b, Secondary progressive multiple sclerosis, Disability progression, Neurology. Diseases of the nervous system, RC346-429
Abstract

Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS patients treated with natalizumab (NTZ) or interferon beta-1b (IFNb-1b). This multicenter retrospective enrolled patients with a diagnosis of SPMS according to 2014 Lublin criteria, who received NTZ or IFNb-1b for at least 48 months between the 1st June 2012 and the 15th May 2018 ​at 33 Italian MS centers contributing to the Italian MS Registry NTZ or IFNb-1b. Confirmed Expanded Disability Status Scale worsening (CEW) and progression independent of relapse (PIRA) were evaluated. In order to correct for non-randomization, a propensity score matching of the groups was performed. Out of 5206 MS patients identified at the time of data extraction, 421 SPMS patients treated with NTZ (224 [53.2%] females, mean age 45.3 ​± ​25.4 years) and 353 with IFNb-1b (133 [37.8%] females, mean age 48.5 ​± ​19.8 years) were enrolled. After applying the matching procedure, 102 patients were retained in the NTZ group and 98 in the IFNb-2b group. The proportion of patients who reached the 48-month 1-point CEW was significantly higher in IFNb-1b compared to NTZ group (58.2% versus 30.4%, p ​= ​0.01). The proportion of patients who developed PIRA at 48 months were significantly higher in IFNb-1b compared to NTZ (72.4% versus 40.2%, p ​= ​0.01). EDSS before treatment initiation and SPMS duration were risk factors for disability progression in terms of PIRA (HR 2.54, 25%CI 1.67–5.7; p ​= ​0.006 and HR 2.04, 25%CI 1.22–3.35; p ​= ​0.01, respectively). Patients treated with IFNb-1b were 1.64 times more to likely to develop PIRA (HR 1.64, 25%CI 1.04–4.87; p ​= ​0.001). Treatment with NTZ in SPMS patients showed more favorable disability outcomes compared to IFNb-1b with beneficial effects over 48 months.

Published
2024
Full Text
View/download PDF

16. Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study

Author

Marcello Moccia, Giuseppina Affinito, Giuseppina Marrazzo, Tiziana Ciarambino, Paolo Di Procolo, Licia Confalonieri, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, and Raffaele Palladino

Subjects
multiple sclerosis, ocrelizumab, treatment, persistence, adherence, costs, Medicine, Internal medicine, RC31-1245, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Abstract

Background: We aim to provide up-to-date real-world evidence on the persistence, adherence, healthcare resource utilization, and costs of multiple sclerosis (MS) by comparing ocrelizumab to other disease-modifying treatments (DMTs) and within different DMT sequences. Methods: We included 3371 people with MS who first received or switched DMT prescriptions from January 2018 to December 2022; they were identified through hospital discharge records, drug prescriptions, and exemption codes from the Campania Region (South Italy). We calculated persistence (time from the first prescription to discontinuation or switching to another DMT), adherence (proportion of days covered (PDC)), DMT costs, and MS hospital admissions and related costs. Results: The most frequently prescribed DMT was dimethyl fumarate (n = 815; age 38.90 ± 11.91 years; 69.5% females), followed by ocrelizumab (n = 682; age 46.46 ± 11.29 years; 56.3%); 28.8% of the patients treated with ocrelizumab were naïve to DMTs. Using ocrelizumab as a statistical reference, the risk of discontinuation was higher for other highly active (HR = 6.32; 95%CI = 3.16, 12.63; p < 0.01) and low-/medium-efficacy DMTs (HR = 10.10; 95%CI = 5.10, 19.77; p < 0.01); adherence was lower for other highly active DMTs (Coeff = −0.07; 95%CI = −0.10, −0.04; p < 0.01) and low-/medium-efficacy DMTs (Coeff = −0.16; 95%CI = −0.19, −0.14; p < 0.01). monthly DMT costs were higher for other highly active DMTs (Coeff = 77.45; 95%CI = 29.36, 125.53; p < 0.01) but lower for low-/medium-efficacy DMTs (Coeff = −772.31; 95%CI = −816.95, −727.66; p < 0.01). The hospital admissions and related costs of MS were similar between ocrelizumab, other highly active DMTs, and other low-/medium-efficacy DMTs, and with ocrelizumab as the first-line DMT after other highly active DMTs and after low-/medium-efficacy DMTs, which was possibly due to the low number of observations. Conclusions: From 2018 to 2022, ocrelizumab was among the most frequently prescribed DMTs, with 28.8% prescriptions to incident MS patients, confirming its relevance in clinical practice. Ocrelizumab was associated with the highest persistence and adherence, pointing towards its favorable benefit–risk profile. The costs of ocrelizumab were lower than those of other highly active DMTs.

Published
2024
Full Text
View/download PDF

17. Effectiveness of Ocrelizumab in Primary Progressive Multiple Sclerosis: a Multicenter, Retrospective, Real-world Study (OPPORTUNITY)

Author

Chisari, Clara G., Bianco, Assunta, Brescia Morra, Vincenzo, Calabrese, Massimiliano, Capone, Fioravante, Cavalla, Paola, Chiavazza, Carlotta, Comi, Cristoforo, Danni, Maura, Filippi, Massimo, Iaffaldano, Pietro, Lanzillo, Roberta, Lo Fermo, Salvatore, Lucisano, Alessandra, Lugaresi, Alessandra, Lus, Giacomo, Marfia, Gerolama Alessandra, Marinelli, Fabiana, Mirabella, Massimiliano, Moiola, Lucia, Perin, Chiara, Realmuto, Sabrina, Toscano, Simona, Trojano, Maria, Vecchio, Domizia, and Patti, Francesco

Published
2023
Full Text
View/download PDF

18. Effectiveness of teriflunomide on No Evidence of Disease Activity and cognition in relapsing remitting multiple sclerosis: results of the NEDA3PLUS study

Author

Amato, Maria Pia, Bergamaschi, Roberto, Centonze, Diego, Mirabella, Massimiliano, Marfia, Girolama Alessandra, Totaro, Rocco, Lus, Giacomo, Brescia Morra, Vincenzo, Aguglia, Umberto, Comi, Cristoforo, Cavalla, Paola, Zaffaroni, Mauro, Rovaris, Marco, Grimaldi, Luigi Maria, Leoni, Stefania, Malucchi, Simona, Baldi, Eleonora, Romano, Marcello, Falcini, Mario, Perini, Paola, Assetta, Maurizio, Portaccio, Emilio, Sommacal, Sergio, Olivieri, Nunzio, Parodi, Franco, Todaro, Daniele Santo, Grassivaro, Nicoletta, Farina, Alberto, Mondino, Margaret Mary, Filippi, Massimo, and Trojano, Maria

Published
2023
Full Text
View/download PDF

19. Disease-modifying therapies in managing disability worsening in paediatric-onset multiple sclerosis: a longitudinal analysis of global and national registries

Author

Horakova, Dana, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Boz, Cavit, Pozzilli, Carlo, Cocco, Eleonora, Gallo, Paolo, Yamout, Bassem, Khoury, Samia J., Lugaresi, Alessandra, Onofrj, Marco, Lus, Giacomo, Clerici, Valentina Torri, Maniscalco, Giorgia Teresa, Romano, Silvia, Tortorella, Carla, Valentino, Paola, Rovaris, Marco, Shaygannejad, Vahid, Ferraro, Diana, Vianello, Marika, Grammond, Pierre, Bergamaschi, Roberto, Gallo, Antonio, Cavalla, Paola, Sa, Maria Jose, Lechner-Scott, Jeannette, Pesci, Ilaria, Buzzard, Katherine, Gouider, Riadh, Mrabet, Saloua, Aguglia, Umberto, Conte, Antonella, Avolio, Carlo, Bellantonio, Paolo, John, Nevin, Cartechini, Elisabetta, De Robertis, Francesca, Ferraro, Elisabetta, Weinstock-Guttman, Bianca, Barcella, Valeria, Van der Walt, Anneke, Butzkueven, Helmut, Coniglio, Maria Gabriella, Granella, Franco, Kuhle, Jens, Marfia, Girolama Alessandra, Laureys, Guy, Van Hijfte, Liesbeth, Maimone, Davide, Gazzola, Paola, Blanco, Yolanda, Turkoglu, Recai, Montepietra, Sara, Spitaleri, Daniele, van Pesch, Vincent, Gerlach, Oliver, Prevost, Julie, Ampapa, Radek, Soysal, Aysun, Altintas, Ayse, Rini, Augusto, Solaro, Claudio, Protti, Alessandra, Foschi, Matteo, Surcinelli, Andrea, Gatto, Maurizia, Mascoli, Nerina, De Riz, Milena, Realmuto, Sabrina, Rossi, Patrizia, Totaro, Rocco, Barnett, Michael, Oh, Jiwon, Nasuelli, Davide, Ramo-Tello, Cristina, Sanchez-Menoyo, Jose Luis, Al-Harbi, Talal, Fioretti, Cristina, Bucello, Sebastiano, Cargnelutti, Daniela, Vukusic, Sandra, Sharmin, Sifat, Roos, Izanne, Malpas, Charles B, Iaffaldano, Pietro, Simone, Marta, Filippi, Massimo, Kubala Havrdova, Eva, Ozakbas, Serkan, Brescia Morra, Vincenzo, Alroughani, Raed, Zaffaroni, Mauro, Patti, Francesco, Eichau, Sara, Salemi, Giuseppe, Di Sapio, Alessia, Inglese, Matilde, Portaccio, Emilio, Trojano, Maria, Amato, Maria Pia, and Kalincik, Tomas

Published
2024
Full Text
View/download PDF

20. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

Author

Bergamaschi, Roberto, Ponzano, Marta, Schiavetti, Irene, Carmisciano, Luca, Cordioli, Cinzia, Filippi, Massimo, Radaelli, Marta, Immovilli, Paolo, Capobianco, Marco, De Rossi, Nicola, Brichetto, Giampaolo, Cocco, Eleonora, Scandellari, Cinzia, Cavalla, Paola, Pesci, Ilaria, Zito, Antonio, Confalonieri, Paolo, Marfia, Girolama Alessandra, Perini, Paola, Inglese, Matilde, Trojano, Maria, Morra, Vincenzo Brescia, Pisoni, Enrico, Tedeschi, Gioacchino, Comi, Giancarlo, Battaglia, Mario Alberto, Patti, Francesco, Salvetti, Marco, Sormani, Maria Pia, Abbadessa, Gianmarco, Aguglia, Umberto, Allegorico, Lia, Allegri, Rossi Beatrice Maria, Alteno, Anastasia, Amato, Maria Pia, Annovazzi, Pietro, Antozzi, Carlo, Appendino, Lucia, Arena, Sebastiano, Baione, Viola, Balgera, Roberto, Barcella, Valeria, Baroncini, Damiano, Barrilà, Caterina, Battaglia, Mario A, Bellacosa, Alessandra, Bellucci, Gianmarco, Bergamaschi, Valeria, Bezzini, Daiana, Biolzi, Beatrice, Bisecco, Alvino, Bonavita, Simona, Borriello, Giovanna, Bosa, Chiara, Bosco, Antonio, Bovis, Francesca, Bozzali, Marco, Brambilla, Laura, Brescia, Morra Vincenzo, Buccafusca, Maria, Bucciantini, Elisabetta, Bucello, Sebastiano, Buscarinu, Maria Chiara, Cabboi, Maria Paola, Calabrese, Massimiliano, Calabria, Francesca, Caleri, Francesca, Camilli, Federico, Caniatti, Luisa Maria, Cantello, Roberto, Capra, Ruggero, Capuano, Rocco, Carta, Patrizia, Celani, Maria Grazia, Cellerino, Maria, Cerqua, Raffaella, Chisari, Clara, Clerici, Raffaella, Clerico, Marinella, Cola, Gaia, Conte, Antonella, Conti, Marta Zaffira, Cordano, Christian, Cordera, Susanna, Corea, Francesco, Correale, Claudio, Cottone, Salvatore, Crescenzo, Francesco, Curti, Erica, d'Ambrosio, Alessandro, and D'Amico, Emanuele

Subjects
Clinical Research, Neurosciences, Multiple Sclerosis, Brain Disorders, Autoimmune Disease, Neurodegenerative, Climate-Related Exposures and Conditions, Good Health and Well Being, Sustainable Cities and Communities, Air Pollution, COVID-19, Humans, Particulate Matter, SARS-CoV-2, MuSC-19 study group, air pollution, coronavirus, multiple sclerosis, Clinical Sciences, Neurology & Neurosurgery
Abstract

Background and purposeSome studies have shown that air pollution, often assessed by thin particulate matter with diameter below 2.5 µg/m3 (PM2.5), may contribute to severe COVID-19 courses, as well as play a role in the onset and evolution of multiple sclerosis (MS). However, the impact of air pollution on COVID-19 has never been explored specifically amongst patients with MS (PwMS). This retrospective observational study aims to explore associations between PM2.5 and COVID-19 severity amongst PwMS.MethodsData were retrieved from an Italian web-based platform (MuSC-19) which includes PwMS with COVID-19. PM2.5 2016-2018 average concentrations were provided by the Copernicus Atmospheric Monitoring Service. Italian patients inserted in the platform from 15 January 2020 to 9 April 2021 with a COVID-19 positive test were included. Ordered logistic regression models were used to study associations between PM2.5 and COVID-19 severity.ResultsIn all, 1087 patients, of whom 13% required hospitalization and 2% were admitted to an intensive care unit or died, were included. Based on the multivariate analysis, higher concentrations of PM2.5 increased the risk of worse COVID-19 course (odds ratio 1.90; p = 0.009).ConclusionsEven if several other factors explain the unfavourable course of COVID-19 in PwMS, the role of air pollutants must be considered and further investigated.

Published
2022

21. Chronic cerebrospinal venous insufficiency in multiple sclerosis: a highly prevalent age-dependent phenomenon

Author

Lanzillo Roberta, Mancini Marcello, Liuzzi Raffaele, Di Donato Orlando, Salvatore Elena, Maglio Valentina, Vacca Giovanni, Amato Luca, D’Anna Gennaro, Brunetti Arturo, and Brescia Morra Vincenzo

Subjects
Multiple sclerosis, Venous insufficiency, Ultrasonography, Neurology. Diseases of the nervous system, RC346-429
Abstract

Abstract Background This study aimed to investigate the prevalence and clinical relevance of chronic cerebrospinal venous insufficiency (CCSVI) in multiple sclerosis (MS) patients and healthy controls using extra- and intracranial colour Doppler sonography. Methods We examined 146 MS patients, presenting with a clinically isolated syndrome, relapsing-remitting, secondary progressive, or primary progressive MS, and 38 healthy controls. Sonographic examination was performed according to Zamboni’s protocol and was performed by three independent sonographers. The results of sonographic examination were compared with clinical and demographic characteristics of the patients. Results CCSVI, defined as the presence of at least two positive Zamboni’s criteria, was found in 76% of MS patients and 16% of control subjects. B-mode anomalies of internal jugular veins, such as stenosis, malformed valves, annuli, and septa were the most common lesions detected in MS patients (80.8%) and controls (47.4%). We observed a positive correlation between sonographic diagnosis of CCSVI and the patients’ age (p = 0.003). However, such a correlation was not found in controls (p = 0.635). Notably, no significant correlations were found between sonographic signs of CCSVI and clinical characteristics of MS, except for absent flow in the jugular veins, which was found more often in primary (p Conclusions Sonographically defined CCSVI is common in MS patients. However, CCSVI appears to be primarily associated with the patient’s age, and poorly correlated with the clinical course of the disease.

Published
2013
Full Text
View/download PDF

23. Sexual dysfunction in multiple sclerosis: The impact of different MSISQ-19 cut-offs on prevalence and associated risk factors

Author

Petracca, M, Carotenuto, A, Scandurra, C, Moccia, M, Rosa, L, Arena, S, Ianniello, A, Nozzolillo, A, Turrini, M, Streito, LM, Abbadessa, G, Cellerino, M, Bucello, S, Ferraro, E, Mattioli, M, Chiodi, A, Inglese, M, Bonavita, S, Clerico, M, Cordioli, C, Moiola, L, Patti, F, Lavorgna, L, Filippi, M, Borriello, G, D'Amico, E, Pozzilli, C, Brescia Morra, V, and Lanzillo, R

Published
2023
Full Text
View/download PDF

24. Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals’ perspective

Author

Lus, Giacomo, Bassano, Marco André, Brescia Morra, Vincenzo, Bonavita, Simona, Gallo, Antonio, Maimone, Davide, Malerba, Laura, Maniscalco, Giorgia Teresa, Saccà, Francesco, Salemi, Giuseppe, Turrini, Renato, Cottone, Salvatore, Sessa, Edoardo, Buccafusca, Maria, and Grimaldi, Luigi Maria Edoardo

Published
2023
Full Text
View/download PDF

26. Radiological Reporting Systems in Multiple Sclerosis

Author

Alessandra Scaravilli, Mario Tranfa, Giuseppe Pontillo, Antonio Carotenuto, Caterina Lapucci, Riccardo Nistri, Elisabetta Signoriello, Marcello Moccia, Carla Tortorella, Ruggero Capra, Giacomo Lus, Matilde Inglese, Claudio Gasperini, Roberta Lanzillo, Carlo Pozzilli, Vincenzo Brescia Morra, Arturo Brunetti, Maria Petracca, and Sirio Cocozza

Subjects
multiple sclerosis, report, quantitative software, atrophy, Technology, Engineering (General). Civil engineering (General), TA1-2040, Biology (General), QH301-705.5, Physics, QC1-999, Chemistry, QD1-999
Abstract

(1) Background: Although MRI is a well-established tool in Multiple Sclerosis (MS) diagnosis and management, neuroradiological reports often lack standardization and/or quantitative information, with possible consequences in clinical care. The aim of this study was to evaluate the impact of information provided by neuroradiological reports and different reporting systems on the clinical management of MS patients. (2) Methods: An online questionnaire was proposed to neurologists working in Italian tertiary care level MS centers. Questions assessed the impact of different MRI-derived biomarkers on clinical choices, the preferred way of receiving radiological information, and the neurologists’ opinions about different reporting systems and the use of automated software in clinical practice. (3) Results: The online survey was completed by 62 neurologists. New/enlarging (100%) lesions, the global T2w/FLAIR lesion load (96.8%), and contrast-enhancing (95.2%) lesions were considered the most important biomarkers for therapeutic decision, while new/enlarging lesions (98.4%), global T2w/FLAIR lesion load (96.8%), and cerebral atrophy (90.3%) were relevant to prognostic evaluations. Almost all participants (98.4%) considered software for medical imaging quantification helpful in clinical management, mostly in relation to prognostic evaluations. (4) Conclusions: These data highlight the impact of providing accurate and reliable data in neuroradiological reports. The use of software for medical imaging quantification in MS can be helpful to standardize radiological reports and to provide useful clinical information to neurologists.

Published
2024
Full Text
View/download PDF

31. Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study

Author

Baroncini, Damiano, Ghezzi, Angelo, Guaschino, Clara, Moiola, Lucia, Filippi, Massimo, Ianniello, Antonio, Pozzilli, Carlo, Lanzillo, Roberta, Brescia-Morra, Vincenzo, Margoni, Monica, Gallo, Paolo, Callari, Graziella, Grimaldi, Luigi, Lus, Giacomo, Calabrese, Massimiliano, Simone, Marta, Marfia, Girolama Alessandra, Rasia, Sarah, Cargnelutti, Daniela, Comi, Giancarlo, and Zaffaroni, Mauro

Published
2022
Full Text
View/download PDF

33. Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4

Author

Diego Centonze, Maria Pia Amato, Vincenzo Brescia Morra, Eleonora Cocco, Nicola De Stefano, Claudio Gasperini, Paolo Gallo, Carlo Pozzilli, Maria Trojano, and Massimo Filippi

Subjects
Neurology. Diseases of the nervous system, RC346-429
Abstract

Multiple sclerosis (MS) is a chronic, progressive neurological disease involving neuroinflammation, neurodegeneration, and demyelination. Cladribine tablets are approved for immune reconstitution therapy in patients with highly active relapsing–remitting MS based on favorable efficacy and tolerability results from the CLARITY study that have been confirmed in long-term extension studies. The approved 4-year dosing regimen foresees a cumulative dose of 3.5 mg/kg administered in two cycles administered 1 year apart, followed by 2 years of observation. Evidence on managing patients beyond year 4 is scarce; therefore, a group of 10 neurologists has assessed the available evidence and formulated an expert opinion on management of the growing population of patients now completing the approved 4-year regimen. We propose five patient categories based on response to treatment during the first 4-year regimen, and corresponding management pathways that envision close monitoring with clinical visits, magnetic resonance imaging (MRI) and/or biomarkers. At the first sign of clinical or radiological disease activity, patients should receive a highly effective disease-modifying therapy, comprising either a full cladribine regimen as described in regulatory documents (cumulative dose 7.0 mg/kg) or a comparably effective treatment. Re-treatment decisions should be based on the intensity and timing of onset of disease activity, clinical and radiological assessments, as well as patient eligibility for treatment and treatment preference.

Published
2023
Full Text
View/download PDF

34. Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich's Ataxia.

Author

Jasoliya, Mittal, Sacca, Francesco, Sahdeo, Sunil, Chedin, Frederic, Pane, Chiara, Brescia Morra, Vincenzo, Filla, Alessandro, Pook, Mark, and Cortopassi, Gino

Subjects
Lymphocytes, Fibroblasts, Animals, Humans, Mice, Friedreich Ataxia, Disease Models, Animal, Iron-Binding Proteins, Mutation, Models, Biological, Transcription Initiation, Genetic, Organelle Biogenesis, Dimethyl Fumarate, Disease Models, Animal, Models, Biological, Transcription Initiation, Genetic, General Science & Technology
Abstract

Friedreich's Ataxia (FA) is an inherited neurodegenerative disorder resulting from decreased expression of the mitochondrial protein frataxin, for which there is no approved therapy. High throughput screening of clinically used drugs identified Dimethyl fumarate (DMF) as protective in FA patient cells. Here we demonstrate that DMF significantly increases frataxin gene (FXN) expression in FA cell model, FA mouse model and in DMF treated humans. DMF also rescues mitochondrial biogenesis deficiency in FA-patient derived cell model. We further examined the mechanism of DMF's frataxin induction in FA patient cells. It has been shown that transcription-inhibitory R-loops form at GAA expansion mutations, thus decreasing FXN expression. In FA patient cells, we demonstrate that DMF significantly increases transcription initiation. As a potential consequence, we observe significant reduction in both R-loop formation and transcriptional pausing thereby significantly increasing FXN expression. Lastly, DMF dosed Multiple Sclerosis (MS) patients showed significant increase in FXN expression by ~85%. Since inherited deficiency in FXN is the primary cause of FA, and DMF is demonstrated to increase FXN expression in humans, DMF could be considered for Friedreich's therapy.

Published
2019

35. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

Author

Gianmarco, Abbadessa, Umberto, Aguglia, Lia, Allegorico, Maria, Allegri Rossi Beatrice, Anastasia, Alteno, Pia, Amato Maria, Pietro, Annovazzi, Carlo, Antozzi, Lucia, Appendino, Sebastiano, Arena, Viola, Baione, Roberto, Balgera, Valeria, Barcella, Damiano, Baroncini, Caterina, Barrilà, Mario A, Battaglia, Alessandra, Bellacosa, Gianmarco, Bellucci, Roberto, Bergamaschi, Valeria, Bergamaschi, Daiana, Bezzini, Beatrice, Biolzi, Alvino, Bisecco, Simona, Bonavita, Giovanna, Borriello, Chiara, Bosa, Antonio, Bosco, Francesca, Bovis, Marco, Bozzali, Laura, Brambilla, Vincenzo, Brescia Morra, Giampaolo, Brichetto, Maria, Buccafusca, Elisabetta, Bucciantini, Sebastiano, Bucello, Chiara, Buscarinu Maria, Paola, Cabboi Maria, Massimiliano, Calabrese, Francesca, Calabria, Francesca, Caleri, Federico, Camilli, Maria, Caniatti Luisa, Roberto, Cantello, Marco, Capobianco, Ruggero, Capra, Rocco, Capuano, Luca, Carmisciano, Patrizia, Carta, Paola, Cavalla, Grazia, Celani Maria, Maria, Cellerino, Raffaella, Cerqua, Clara, Chisari, Raffaella, Clerici, Marinella, Clerico, Eleonora, Cocco, Gaia, Cola, Giancarlo, Comi, Paolo, Confalonieri, Antonella, Conte, Zaffira, Conti Marta, Christian, Cordano, Susanna, Cordera, Cinzia, Cordioli, Francesco, Corea, Claudio, Correale, Salvatore, Cottone, Francesco, Crescenzo, Erica, Curti, Alessandro, d'Ambrosio, Emanuele, D'Amico, Chiara, Danni Maura, Alessia, d'Arma, Vincenzo, Dattola, Stefano, de Biase, Giovanna, De Luca, Federica, De Mercanti Stefania, Paolo, De Mitri, Nicola, De Rossi, Nicola, De Stefano, Maria, Della Cava Fabio, Marco, Della Cava, Sonia, Di Lemme, Mario, di Napoli, Alessia, Di Sapio, Renato, Docimo, Anna, Dutto, Luana, Evangelista, Salvatore, Fanara, Roberta, Fantozzi, Diana, Ferraro, Teresa, Ferrò Maria, Massimo, Filippi, Cristina, Fioretti, Mario, Fratta, Jessica, Frau, Marzia, Fronza, Roberto, Furlan, Alberto, Gajofatto, Antonio, Gallo, Paolo, Gallo, Claudio, Gasperini, Anna, Ghazaryan, Bruno, Giometto, Francesca, Gobbin, Flora, Govone, Franco, Granella, Erica, Grange, Grazia, Grasso Maria, Luigi ME, Grimaldi, Angelica, Guareschi, Clara, Guaschino, Simone, Guerrieri, Donata, Guidetti, Barbara, Juergenson Ina, Pietro, Iaffaldano, Antonio, Ianniello, Luigi, Iasevoli, Paolo, Immovilli, Daniele, Imperiale, Teresa, Infante Maria, Matilde, Inglese, Rosa, Iodice, Aniello, Iovino, Giovanna, Konrad, Doriana, Landi, Roberta, Lanzillo, Caterina, Lapucci, Luigi, Lavorgna, Rita, L'Episcopo Maria, Serena, Leva, Giuseppe, Liberatore, Marianna, Lo Re, Marco, Longoni, Leonardo, Lopiano, Lorena, Lorefice, Matteo, Lucchini, Giacomo, Lus, Davide, Maimone, Maria, Malentacchi, Giulia, Mallucci, Simona, Malucchi, Rosa, Mancinelli Chiara, Luca, Mancinelli, Paolo, Manganotti, Teresa, Maniscalco Giorgia, Vittorio, Mantero, Sabrina, Marangoni, Damiano, Marastoni, Alessandra, Marfia Girolama, Fabiana, Marinelli, Alessandro, Marti, Filippo, Martinelli Boneschi, Federco, Masserano Zoli, Francesca, Matta, Laura, Mendozzi, Giuseppe, Meucci, Silvia, Miante, Giuseppina, Miele, Eva, Milano, Massimiliano, Mirabella, Rosanna, Missione, Marcello, Moccia, Lucia, Moiola, Sara, Montepietra, Margherita, MontiBragadin, Federico, Montini, Roberta, Motta, Raffaele, Nardone, Gabri, Nicoletti Carolina, Eduardo, Nobile-Orazio, Agostino, Nozzolillo, Marco, Onofrj, Riccardo, Orlandi, Anna, Palmieri, Damiano, Paolicelli, Livia, Pasquali, Fulvio, Pasquin, Luisa, Pastò, Francesco, Patti, Elisabetta, Pedrazzoli, Paola, Perini, Ilaria, Pesci, Maria, Petracca, Alfredo, Petrone, Carlo, Piantadosi, Anna M, Pietroboni, Federica, Pinardi, Marta, Ponzano, Emilio, Portaccio, Mattia, Pozzato, Carlo, Pozzilli, Luca, Prosperini, Alessandra, Protti, Eugenio, Pucci, Marta, Radaelli, Paolo, Ragonese, Sarah, Rasia, Sabrina, Realmuto, Anna, Repice, Eleonora, Rigoni, Teresa, Rilla Maria, Francesca, Rinaldi, Marcello, Romano Calogero, Marco, Ronzoni, Marco, Rovaris, Francesca, Ruscica, Loredana, Sabattini, Giuseppe, Salemi, Marco, Salvetti, Lorenzo, Saraceno, Alessia, Sartori, Arianna, Sartori, Elvira, Sbragia, Cinzia, Scandellari, Ilaria, Scarano Giuditta, Valentina, Scarano, Irene, Schiavetti, Maria, Sessa, Caterina, Sgarito, Grazia, Sibilia, Gabriele, Siciliano, Alessio, Signori, Elisabetta, Signoriello, Leonardo, Sinisi, Francesca, Sireci, Patrizia, Sola, Claudio, Solaro, Pia, Sormani Maria, Stefano, Sotgiu, Maddalena, Sparaco, Laura, Stromillo Maria, Silvia, Strumia, Laura, Susani Emanuela, Giulietta, Tabiadon, Francesco, Teatini, Gioacchino, Tedeschi, Valentina, Tomassini, Simone, Tonietti, Valentina, Torri Clerici, Carla, Tortorella, Simona, Toscano, Rocco, Totaro, Maria, Trojano, Maria, Trotta, Gabriella, Turano, Monica, Ulivelli, Manzo, Valentino, Giovanna, Vaula, Domizia, Vecchio, Marco, Vercellino, Pinuccia, Verrengia Elena, Marika, Vianello, Eleonora, Virgilio, Francesca, Vitetta, Stefano, Vollaro, Mauro, Zaffaroni, Mauro, Zampolini, Roberto, Zarbo Ignazio, Antonio, Zito, Luigi, Zuliani, Ponzano, Marta, Schiavetti, Irene, Bergamaschi, Roberto, Pisoni, Enrico, Bellavia, Andrea, Mallucci, Giulia, Carmisciano, Luca, Inglese, Matilde, Cordioli, Cinzia, Marfia, Girolama Alessandra, Cocco, Eleonora, Immovilli, Paolo, Pesci, Ilaria, Scandellari, Cinzia, Cavalla, Paola, Radaelli, Marta, Vianello, Marika, Vitetta, Francesca, Montepietra, Sara, Amato, Maria Pia, Fioretti, Cristina, Filippi, Massimo, Sartori, Arianna, Caleri, Francesca, Clerico, Marinella, Gallo, Antonio, Conte, Antonella, Clerici, Raffaella, De Luca, Giovanna, Boneschi, Filippo Martinelli, Cantello, Roberto, Calabrese, Massimiliano, Tortorella, Carla, Rovaris, Marco, Verrengia, Elena Pinuccia, Patti, Francesco, Morra, Vincenzo Brescia, Salvetti, Marco, and Sormani, Maria Pia

Published
2022
Full Text
View/download PDF

36. Corrigendum: A two-year longitudinal study of retinal vascular impairment in patients with amnestic mild cognitive impairment

Author

Chiara Criscuolo, Gilda Cennamo, Daniela Montorio, Antonio Carotenuto, Miriana Migliaccio, Marcello Moccia, Elena Salvatore, Roberta Lanzillo, Ciro Costagliola, and Vincenzo Brescia Morra

Subjects
OCTA, aMCI, Alzheimer's disease, longitudinal study, mini mental state examination, Neurosciences. Biological psychiatry. Neuropsychiatry, RC321-571
Published
2023
Full Text
View/download PDF

38. Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis

Author

Zappulo, Emanuela, Buonomo, Antonio Riccardo, Moccia, Marcello, Pinchera, Biagio, Villari, Riccardo, Petracca, Maria, Lanzillo, Roberta, Scotto, Riccardo, Carotenuto, Antonio, Viceconte, Giulio, Schiano Moriello, Nicola, Bruno, Luca, Gentile, Ivan, and Brescia Morra, Vincenzo

Published
2022
Full Text
View/download PDF

39. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study

Author

Buonomo, Antonio Riccardo, Viceconte, Giulio, Calabrese, Massimiliano, De Luca, Giovanna, Tomassini, Valentina, Cavalla, Paola, Maniscalco, Giorgia Teresa, Ferraro, Diana, Nociti, Viviana, Radaelli, Marta, Buscarinu, Maria Chiara, Paolicelli, Damiano, Gajofatto, Alberto, Annovazzi, Pietro, Pinardi, Federica, Di Filippo, Massimiliano, Cordioli, Cinzia, Zappulo, Emanuela, Scotto, Riccardo, Gentile, Ivan, Spiezia, Antonio Luca, Petruzzo, Martina, De Angelis, Marcello, Brescia Morra, Vincenzo, Solaro, Claudio, Gasperini, Claudio, Cocco, Eleonora, Moccia, Marcello, and Lanzillo, Roberta

Published
2022
Full Text
View/download PDF

41. Dysphagia assessment in patients with multiple sclerosis – an additional piece to disability burden.

Author

Ranucci, Davide, Falco, Fabrizia, Nicolella, Valerio, Di Monaco, Cristina, Migliaccio, Laura, Lamagna, Federica, Caracciolo, Federica, Eliano, Martina, Petracca, Maria, Moccia, Marcello, Brescia Morra, Vincenzo, Carotenuto, Antonio, and Lanzillo, Roberta

Subjects
SLEEP quality, ASPIRATION pneumonia, FATIGUE (Physiology), MENTAL depression, DEGLUTITION disorders
Abstract

Objective: People with multiple sclerosis (MS) might experience symptoms that are usually underestimated. Dysphagia should be evaluated within the Expanded Disability Status Scale (EDSS), but clinicians often do not assess it properly. The objectives of this study are as follows: To assess the prevalence of dysphagia in patients with MS utilizing the Swallowing Disturbance Questionnaire (SDQ); to examine the correlation with the EDSS; to investigate the relationship between dysphagia and clinico‐demographic characteristics of MS. Methods: In total, 177 MS patients underwent evaluations with EDSS, SDQ, cognitive functions, anxiety, depression, fatigue, and sleep quality tests. We compared clinico‐demographic data of patients with and without dysphagia and native‐EDSS to SDQ‐EDSS. Results: Out of the 177 MS patients, 56% of individuals were identified having dysphagia according to the SDQ with 41 patients exhibiting mild dysphagia, 31 showing moderate dysphagia and 27 patients having severe dysphagia. Only 6 patients had dysphagia recorded in the EDSS. SDQ‐EDSS scores were significantly higher than native scores. Dysphagia was associated with depressive symptoms and sleep quality. Interpretation: Dysphagia affects up to 56% of MS patients. The SDQ questionnaire is useful for identifying dysphagia, which can help in capturing disease progression and preventing complications like aspiration pneumonia. The SDQ‐EDSS was higher than the native‐EDSS, reflecting the poor ability of the native‐EDSS to evaluate certain symptoms such as dysphagia. The SDQ correlated with depressive symptoms, which are associated with a greater perception of MS symptoms, and poor sleep quality, which could be associated with the triggering of pathogenic mechanisms responsible for disease progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study

Author

Chisari, Clara G., Comi, Giancarlo, Filippi, Massimo, Paolicelli, Damiano, Iaffaldano, Pietro, Zaffaroni, Mauro, Brescia Morra, Vincenzo, Cocco, Eleonora, Marfia, Girolama Alessandra, Grimaldi, Luigi Maria, Inglese, Matilde, Bonavita, Simona, Lugaresi, Alessandra, Salemi, Giuseppe, De Luca, Giovanna, Cottone, Salvatore, Conte, Antonella, Sola, Patrizia, Aguglia, Umberto, Maniscalco, Giorgia Teresa, Gasperini, Claudio, Ferrò, Maria Teresa, Pesci, Ilaria, Amato, Maria Pia, Rovaris, Marco, Solaro, Claudio, Lus, Giacomo, Maimone, Davide, Bergamaschi, Roberto, Granella, Franco, Di Sapio, Alessia, Bertolotto, Antonio, Totaro, Rocco, Vianello, Marika, Cavalla, Paola, Bellantonio, Paolo, Lepore, Vito, and Patti, Francesco

Published
2022
Full Text
View/download PDF

44. Cognitive trajectories in multiple sclerosis: a long-term follow-up study

Author

Carotenuto, Antonio, Costabile, Teresa, Pontillo, Giuseppe, Moccia, Moccia, Falco, Fabrizia, Petracca, Maria, Petruzzo, Martina, Russo, Cinzia Valeria, Di Stasi, Martina, Paolella, Chiara, Perillo, Teresa, Vola, Elena Augusta, Cipullo, Maria Brunella, Cocozza, Sirio, Lanzillo, Roberta, Brescia Morra, Vincenzo, and Saccà, Francesco

Published
2022
Full Text
View/download PDF

46. Clinical validation in multiple sclerosis of the lumipulse immunoassay for plasma neurofilament light chain

Author

Fiorenza, M., primary, Carbone, G., additional, La Civita, E., additional, Felicelli, G., additional, Sansone, R., additional, Delle Cave, T., additional, D’Angelo, M., additional, Sirica, R., additional, Jannuzzi, G., additional, Nicolella, V., additional, Moccia, M., additional, Brescia Morra, V., additional, and Terracciano, D., additional

Published
2024
Full Text
View/download PDF

47. Incidence and prevalence of dementia: A 2015-2020 population-based study in the Campania Region of Italy

Author

Affinito, Giuseppina, primary, Salerno, Vito, additional, Di Gennaro, Massimo, additional, Scafa, Luca, additional, Russo, Alessandro, additional, Fumo, Maria Grazia, additional, Giordana, Roberta, additional, Falco, Fabrizia, additional, Della Pia, Flavio, additional, Di Cecca, Angelica, additional, Migliaccio, Miriana, additional, Ilardi, Ciro Rosario, additional, Criscuolo, Chiara, additional, Spisto, Myriam, additional, Triassi, Maria, additional, Brescia Morra, Vincenzo, additional, Palladino, Raffaele, additional, Salvatore, Elena, additional, and Moccia, Marcello, additional

Published
2024
Full Text
View/download PDF

48. Spectral Domain and Angiography Optical Coherence Tomography in Parkinson’s Disease: Structural And Vascular Changes in the Retina Correlate with Disease Severity and Progression

Author

Di Maio, Laura Giovanna, primary, Cennamo, Gilda, additional, Montorio, Daniela, additional, De Michele, Giovanna, additional, Palmieri, Gianluigi Rosario, additional, Baratto, Luigi, additional, Perillo, Sandra, additional, Giglio, Augusta, additional, Filla, Alessandro, additional, Brescia Morra, Vincenzo, additional, De Michele, Giuseppe, additional, Costagliola, Ciro, additional, and De Rosa, Anna, additional

Published
2024
Full Text
View/download PDF

50. Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential

Author

Procaccini, Claudio, Garavelli, Silvia, Carbone, Fortunata, Di Silvestre, Dario, La Rocca, Claudia, Greco, Dario, Colamatteo, Alessandra, Lepore, Maria Teresa, Russo, Claudia, De Rosa, Giusy, Faicchia, Deriggio, Prattichizzo, Francesco, Grossi, Sarah, Campomenosi, Paola, Buttari, Fabio, Mauri, Pierluigi, Uccelli, Antonio, Salvetti, Marco, Brescia Morra, Vincenzo, Vella, Danila, Galgani, Mario, Mottola, Maria, Zuccarelli, Bruno, Lanzillo, Roberta, Maniscalco, Giorgia Teresa, Centonze, Diego, de Candia, Paola, and Matarese, Giuseppe

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results